S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
3 Reliable Growing Dividends Near Rock-Bottom Prices
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
The Strategic Gold Play You Haven't Heard About (Ad)
5 Short Squeeze Candidates With Catalysts For Rebounds
EU announces plans to better protect its sensitive technologies from foreign snooping
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
3 Reliable Growing Dividends Near Rock-Bottom Prices
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
The Strategic Gold Play You Haven't Heard About (Ad)
5 Short Squeeze Candidates With Catalysts For Rebounds
EU announces plans to better protect its sensitive technologies from foreign snooping
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
3 Reliable Growing Dividends Near Rock-Bottom Prices
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
The Strategic Gold Play You Haven't Heard About (Ad)
5 Short Squeeze Candidates With Catalysts For Rebounds
EU announces plans to better protect its sensitive technologies from foreign snooping
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
Would Buffett Approve of This Growth Strategy? (Ad)
Low PE Growth Stocks: Unlocking Investment Opportunities
3 Reliable Growing Dividends Near Rock-Bottom Prices
Would Buffett Approve of This Growth Strategy? (Ad)
Why Ralph Lauren Should Be On Your Holiday Wishlist
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
The Strategic Gold Play You Haven't Heard About (Ad)
5 Short Squeeze Candidates With Catalysts For Rebounds
EU announces plans to better protect its sensitive technologies from foreign snooping
NASDAQ:SPPI

Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$1.03
▼
$1.03
50-Day Range
$0.94
▼
$1.03
52-Week Range
$0.32
▼
$1.57
Volume
N/A
Average Volume
1.93 million shs
Market Capitalization
$211.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.44
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Spectrum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
136.7% Upside
$2.44 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.14) to $0.07 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

737th out of 965 stocks

Pharmaceutical Preparations Industry

352nd out of 449 stocks

See Top Rated MarketRank™ Stocks Here

SPPI stock logo

About Spectrum Pharmaceuticals (NASDAQ:SPPI) Stock

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.


SPPI Stock News Headlines

July 24, 2023 | seekingalpha.com
Buy Spectrum Pharmaceuticals For Exposure To Assertio Holdings
July 8, 2023 | fool.com
Spectrum Pharmaceuticals (NASDAQ: SPPI)
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
July 3, 2023 | benzinga.com
Moore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law Firm
June 30, 2023 | finance.yahoo.com
SPPI - Spectrum Pharmaceuticals, Inc.
May 26, 2023 | msn.com
HC Wainwright & Co. Reiterates Spectrum Pharmaceuticals (SPPI) Neutral Recommendation
May 17, 2023 | finance.yahoo.com
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 15, 2023 | msn.com
Jefferies Downgrades Spectrum Pharmaceuticals (SPPI)
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
May 14, 2023 | finance.yahoo.com
News Flash: Analysts Just Made A Captivating Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts
May 10, 2023 | finance.yahoo.com
Q1 2023 Assertio Holdings Inc Earnings Call
May 9, 2023 | msn.com
Spectrum Pharmaceuticals rises as co. says its Q1 net sales up 54% Q/Q
May 9, 2023 | finance.yahoo.com
Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates
May 5, 2023 | markets.businessinsider.com
B.Riley Financial Remains a Hold on Spectrum Pharmaceuticals (SPPI)
May 1, 2023 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing Investigations
April 30, 2023 | benzinga.com
Lifshitz Law PLLC Announces Investigations of HOTH, ASRT, SPPI, and CEI
April 28, 2023 | benzinga.com
Moore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law Firm
April 27, 2023 | benzinga.com
SHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.
April 27, 2023 | benzinga.com
Spectrum Pharmaceuticals Stock (NASDAQ:SPPI), Short Interest Report
April 26, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Spectrum Pharmaceuticals, Inc. Buyout
April 26, 2023 | markets.businessinsider.com
Expert Ratings for Spectrum Pharma
April 26, 2023 | msn.com
HC Wainwright & Co. Downgrades Spectrum Pharmaceuticals (SPPI)
April 26, 2023 | msn.com
JMP Securities Downgrades Spectrum Pharmaceuticals (SPPI)
April 26, 2023 | markets.businessinsider.com
JMP Securities downgrades Spectrum Pharmaceuticals (SPPI) to a Hold
April 26, 2023 | benzinga.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Spectrum Pharmaceuticals, Inc.
April 25, 2023 | marketwatch.com
Assertio to Acquire Outstanding Shares of Spectrum Pharmaceuticals
April 25, 2023 | seekingalpha.com
Assertio to acquire Spectrum in all stock deal, sending stocks on opposite paths
See More Headlines
Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Company Calendar

Last Earnings
11/10/2021
Today
10/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
CIK
831547
Web
www.sppirx.com
Phone
(617) 586-3900
Fax
702-260-7405
Employees
86
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$2.44
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$0.75
Forecasted Upside/Downside
+136.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,400,000.00
Net Margins
N/A
Pretax Margin
-263.04%
Return on Equity
-218.44%
Return on Assets
-66.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.71
Quick Ratio
2.38

Sales & Book Value

Annual Sales
$10.11 million
Price / Sales
20.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.15 per share
Price / Book
6.87

Miscellaneous

Outstanding Shares
205,250,000
Free Float
199,704,000
Market Cap
$211.41 million
Optionable
Optionable
Beta
2.15

Social Links

A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Thomas J. RigaMr. Thomas J. Riga (Age 48)
    Pres, CEO & Director
    Comp: $1.07M
  • Ms. Nora E. Brennan (Age 54)
    Exec. VP & CFO
    Comp: $46.25k
  • Mr. Keith M. McGahan J.D.Mr. Keith M. McGahan J.D. (Age 47)
    L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec.
    Comp: $948.26k
  • Mr. Michael A. Grabow
    Exec. VP & Chief Bus. Officer
  • Dr. Lyndah K. Dreiling M.B.A.
    M.D., Sr. VP of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SPPI Stock - Frequently Asked Questions

Should I buy or sell Spectrum Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares.
View SPPI analyst ratings or view top-rated stocks.

What is Spectrum Pharmaceuticals' stock price forecast for 2023?

5 equities research analysts have issued 1 year target prices for Spectrum Pharmaceuticals' shares. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they anticipate the company's stock price to reach $2.44 in the next year. This suggests a possible upside of 136.7% from the stock's current price.
View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07. During the same period last year, the firm posted ($0.37) EPS.

What ETF holds Spectrum Pharmaceuticals' stock ?

IQ Merger Arbitrage ETF holds 1,389,760 shares of SPPI stock, representing 0.29% of its portfolio.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $1.03.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $211.41 million and generates $10.11 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (617) 586-3900, via email at ir@sppirx.com, or via fax at 702-260-7405.

This page (NASDAQ:SPPI) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -